Catalent Inc
NYSE:CTLT

Watchlist Manager
Catalent Inc Logo
Catalent Inc
NYSE:CTLT
Watchlist
Price: 60.98 USD 2.21% Market Closed
Market Cap: 11.1B USD
Have any thoughts about
Catalent Inc?
Write Note

Catalent Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Catalent Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Catalent Inc
NYSE:CTLT
PP&E Net
$3.7B
CAGR 3-Years
12%
CAGR 5-Years
18%
CAGR 10-Years
16%
Johnson & Johnson
NYSE:JNJ
PP&E Net
$20.5B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
PP&E Net
$8.3B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
7%
Pfizer Inc
NYSE:PFE
PP&E Net
$19B
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
5%
Merck & Co Inc
NYSE:MRK
PP&E Net
$23.4B
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
PP&E Net
$16.2B
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
7%
No Stocks Found

Catalent Inc
Glance View

Market Cap
11B USD
Industry
Pharmaceuticals

Catalent Inc. is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and consumer health products. Founded in 2007, the company has rapidly grown its footprint by offering innovative solutions that enhance drug formulation and accelerate time to market. With a portfolio that spans from drug development to commercialization, Catalent’s core mission is to improve patient outcomes by ensuring that life-changing therapies reach those who need them. The company operates state-of-the-art manufacturing facilities across the globe, fostering strong partnerships with both small biotechnology firms and large pharmaceutical corporations to optimize their products and processes. As an investor, understanding Catalent's strategic direction is vital. The company capitalizes on the booming demand for biopharmaceuticals and personalized medicines, driven by trends in population aging and the ongoing need for advanced therapeutics. Catalent's commitment to research and innovation is evidenced by its robust R&D investments and a diverse range of proprietary technologies, such as its softgel and Zydis® orally disintegrating tablet technologies. Furthermore, the company's recent expansions and acquisitions signal a strategic focus on enhancing capacity and capabilities, positioning it well to thrive in a highly competitive market. By leveraging its extensive expertise and global scale, Catalent aims not only to enhance its service offerings but to deliver sustained value to its shareholders, making it a compelling option for those seeking exposure to the dynamic healthcare sector.

CTLT Intrinsic Value
59.97 USD
Overvaluation 2%
Intrinsic Value
Price

See Also

What is Catalent Inc's PP&E Net?
PP&E Net
3.7B USD

Based on the financial report for Sep 30, 2024, Catalent Inc's PP&E Net amounts to 3.7B USD.

What is Catalent Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
16%

Over the last year, the PP&E Net growth was -1%. The average annual PP&E Net growth rates for Catalent Inc have been 12% over the past three years , 18% over the past five years , and 16% over the past ten years .

Back to Top